Skip to main content
Erschienen in:

27.01.2022 | Letter to the Editor

In response to the study “a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient’s satisfaction” by Dr. Zylla and colleagues

verfasst von: Mellar P. Davis

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor …
Literatur
1.
Zurück zum Zitat Zylla DM, Eklund J, Gilmore G et al (2021) A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29(12):7471–7478CrossRef Zylla DM, Eklund J, Gilmore G et al (2021) A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29(12):7471–7478CrossRef
2.
Zurück zum Zitat Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167–179CrossRef Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167–179CrossRef
3.
Zurück zum Zitat Portenoy RK, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449CrossRef Portenoy RK, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449CrossRef
4.
Zurück zum Zitat Fallon MT, Albert Lux E, McQuade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11(3):119–133CrossRef Fallon MT, Albert Lux E, McQuade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11(3):119–133CrossRef
5.
Zurück zum Zitat Lichtman AH, Lux EA, McQuade R et al (2018) Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55(2):179-188 e171CrossRef Lichtman AH, Lux EA, McQuade R et al (2018) Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55(2):179-188 e171CrossRef
6.
Zurück zum Zitat Maguire DR, France CP (2018) Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology 235(8):2357–2365CrossRef Maguire DR, France CP (2018) Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology 235(8):2357–2365CrossRef
7.
Zurück zum Zitat Maguire DR, France CP (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217–224CrossRef Maguire DR, France CP (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217–224CrossRef
8.
Zurück zum Zitat Maguire DR, France CP (2016) Additive antinociceptive effects of mixtures of the kappa-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats. Behav Pharmacol 27(1):69–72CrossRef Maguire DR, France CP (2016) Additive antinociceptive effects of mixtures of the kappa-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats. Behav Pharmacol 27(1):69–72CrossRef
9.
Zurück zum Zitat Maguire DR, France CP (2014) Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther 351(2):383–389CrossRef Maguire DR, France CP (2014) Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther 351(2):383–389CrossRef
10.
Zurück zum Zitat Ioannidis JPA (2017) The reproducibility wars: successful, unsuccessful, uninterpretable, exact, conceptual, triangulated, contested replication. Clin Chem 63(5):943–945CrossRef Ioannidis JPA (2017) The reproducibility wars: successful, unsuccessful, uninterpretable, exact, conceptual, triangulated, contested replication. Clin Chem 63(5):943–945CrossRef
11.
Zurück zum Zitat Ioannidis JPA (2018) Why replication has more scientific value than original discovery. Behav Brain Sci 41:e137CrossRef Ioannidis JPA (2018) Why replication has more scientific value than original discovery. Behav Brain Sci 41:e137CrossRef
12.
Zurück zum Zitat Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064CrossRef Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064CrossRef
Metadaten
Titel
In response to the study “a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient’s satisfaction” by Dr. Zylla and colleagues
verfasst von
Mellar P. Davis
Publikationsdatum
27.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06768-8

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.